TLR5 agonists are promising anticancer agents because of their safety, as well as their efficacy. Unlike many other TLRs, TLR5 signaling, while immunostimulatory, does not induce certain highly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback